The Pharmacy Times® Alzheimer Disease Resource Center is a comprehensive resource for clinical news and expert insights on treatments for Alzheimer disease.
March 8th 2024
The FDA is convening a committee to discuss phase 3 data after the planned action date, which delays drug availability to patients.
Study: Machine Learning Can Predict Early Alzheimer Disease, But Has Racial, Ethnic Unfairness
January 5th 2024Although machine learning models demonstrate potential to improve early detection of Alzheimer disease, sample sizes that underrepresent ethnic and racial groups result in unfairness.
Read More
Cognitive Tests Via Smartphone Help Identify Early Amyloid Changes Associated With Alzheimer Disease
January 4th 2024The pattern for the diminished learning curve, associated with elevated amyloid levels, was consistent across 3 memory tasks, with strongest results for recalling digit-signs and groceries prices.
Read More
Clinical Overview: Comparison of Anti-Amyloid Monoclonal Antibodies for Alzheimer Disease
October 11th 2023Aducanumab, lecanemab, and donanemab are novel monoclonal antibodies designed to slow disease progression and hopefully have a positive impact in the field of Alzheimer disease management.
Read More
Anti-Amyloid Monoclonal Antibody Drugs Continue to Show Promise Treating Alzheimer Disease
July 24th 2023New anti-amyloid monoclonal antibody drugs for Alzheimer disease have produced encouraging results in targeting the accumulation of amyloid beta plaques; however, questions remain regarding the risk-benefit profile and cost implications.
Read More